OncoMatch/Clinical Trials/NCT06813365
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
Is NCT06813365 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies DZD6008 for nonsmall-cell lung cancer.
Treatment: DZD6008 — This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Documentation of EGFR sensitizing mutation (Exon19del and/or L858R)
Required: EGFR l858r
Documentation of EGFR sensitizing mutation (Exon19del and/or L858R)
Excluded: EGFR g719x
Carry any other known EGFR alterations, including but not limited to uncommon EGFR mutations (G719X, S768I, L861Q, exon 20 insertions, etc.)
Excluded: EGFR s768i
Carry any other known EGFR alterations, including but not limited to uncommon EGFR mutations (G719X, S768I, L861Q, exon 20 insertions, etc.)
Excluded: EGFR l861q
Carry any other known EGFR alterations, including but not limited to uncommon EGFR mutations (G719X, S768I, L861Q, exon 20 insertions, etc.)
Excluded: EGFR exon 20 insertion
Carry any other known EGFR alterations, including but not limited to uncommon EGFR mutations (G719X, S768I, L861Q, exon 20 insertions, etc.)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor
Failed (progressed or are intolerant) at least 1 prior EGFR TKI
Must have received: platinum-based chemotherapy
Failed (progressed or are intolerant) at least 1 prior ... platinum-based chemotherapy
Lab requirements
Blood counts
Adequate hematopoietic and other organ system functions
Adequate hematopoietic and other organ system functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06813365 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received EGFR tyrosine kinase inhibitor and platinum-based chemotherapy.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR l858r is a required biomarker for enrollment.
Are patients with EGFR alterations eligible?
No. EGFR g719x is an exclusion criterion.
Are patients with EGFR alterations eligible?
No. EGFR s768i is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages